Journal
CANCERS
Volume 14, Issue 4, Pages -Publisher
MDPI
DOI: 10.3390/cancers14040911
Keywords
antibodies; cancer; drug delivery; glycans; glycosylation; nanoparticles
Categories
Funding
- Norte Portugal Regional Operational Programme (NORTE 2020), under the PORTUGAL 2020 Partnership Agreement, through the European Regional Development Fund (FEDER) [Norte-01-0145-FEDER-000051]
- Portuguese Foundation for Science and Technology (FCT) [PTDC/MEC-ONC/0491/2021, SFRH/BD/137896/2018]
- Fundação para a Ciência e a Tecnologia [SFRH/BD/137896/2018, PTDC/MEC-ONC/0491/2021] Funding Source: FCT
Ask authors/readers for more resources
Alterations in glycosylation are commonly observed in cancer cells. Strategies targeting cancer-associated glycans, such as monoclonal antibodies, antibody-drug conjugates, and nanoparticles, have the potential to improve drug delivery to tumor cells and enhance therapeutic efficacy. Nanoparticles can also be used for drug delivery in cancer therapy, including encapsulating vaccines and targeting glycoproteins or glycan-binding proteins. These strategies have significant potential for personalized treatment approaches in the pharmaceutical and clinical sectors.
Simple Summary Alterations in glycosylation are frequently observed in cancer cells. Different strategies have been proposed to increase drug delivery to the tumor site in order to improve the therapeutic efficacy of anti-cancer drugs and avoid collateral cytotoxicity. The exploitation of drug delivery approaches directed to cancer-associated glycans has the potential to pave the way for better and more efficient personalized treatment practices. Such strategies taking advantage of aberrant cell surface glycosylation patterns enhance the targeting efficiency and optimize the delivery of clinically used drugs to cancer cells, with major potential for the clinical applications. Innovative strategies have been proposed to increase drug delivery to the tumor site and avoid cytotoxicity, improving the therapeutic efficacy of well-established anti-cancer drugs. Alterations in normal glycosylation processes are frequently observed in cancer cells and the resulting cell surface aberrant glycans can be used as direct molecular targets for drug delivery. In the present review, we address the development of strategies, such as monoclonal antibodies, antibody-drug conjugates and nanoparticles that specific and selectively target cancer-associated glycans in tumor cells. The use of nanoparticles for drug delivery encompasses novel applications in cancer therapy, including vaccines encapsulated in synthetic nanoparticles and specific nanoparticles that target glycoproteins or glycan-binding proteins. Here, we highlight their potential to enhance targeting approaches and to optimize the delivery of clinically approved drugs to the tumor microenvironment, paving the way for improved personalized treatment approaches with major potential importance for the pharmaceutical and clinical sectors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available